Corporate | 2 February 2005 09:24

Eckert & Ziegler: Strong Growth in the Fiscal Year 2004

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. —————————————————————————— Eckert & Ziegler: Strong Growth in the Fiscal Year 2004 Berlin, February 2nd 2005 – Eckert & Ziegler AG, a manufacturer of medical technology products for the diagnosis and treatment of cancer, was able to greatly increase its earnings and sales volume in its 2004 fiscal year. According to a preliminary assessment, Group sales volume rose by about 18% to EUR 35 million, despite the unfavorable dollar rate development over the course of the year. The annual surplus after taxes more than tripled from EUR 0.28 to around EUR 1.05 per share, although approx. EUR 0.45 of that resulted from a one-time deconsolidation of biotechnology activities. For the coming year, the Executive Board expects a renewed increase in sales volume in the double-digit percentage range, and an annual surplus of EUR 0.50 to 0.80 per share – both without taking acquisitions into account. The exact figures for fiscal 2004 are to be announced at a financial statement press conference on March 30th, when the annual report is to be presented. The Executive Board Your contact for enquiries: Eckert & Ziegler AG Karolin Riehle, Investor Relations Robert-Rössle-Str. 10 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138 http://www.ezag.de end of message, (c)DGAP 02.02.2005 —————————————————————————— WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 020924 Feb 05